A Phase 1 interventional study of WTX-330 in Advanced or Metastatic Solid Tumors and Non-Hodgkin Lymphoma, sponsored by Werewolf Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Werewolf Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 253 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.
Among the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 846th largest by enrollment of the 1,378 interventional ones that give a count, is one of 55 that started in 2022, is one of 529 in phase 1, and was the 1,491st registered.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →137 of the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:
Umoja Biopharma · Sites in United States
Ages 18+
University of Arizona · Sites in United States
Ages up to 65
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Paolo Caimi, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,600 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 734 · Phase 2 730 · Phase 3 117 · Phase 4 9
First in 1986; this study’s year is marked. 55 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 35 across the 1,378 interventional studies, 91 across the 110 observational. Of the 1,249 that completed or were terminated, 505 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
514 of 1,600 have an industry lead sponsor. The 10 most frequent:
Werewolf Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Werewolf Therapeutics, Inc. has 2 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
84 of the studies in Lymphoma, Non-Hodgkin with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
This is a first-in-human, Phase 1, open-label, multicenter study to evaluate the safety, tolerability and preliminary efficacy of WTX-330, a conditionally-activated IL-12 prodrug, when administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. Dose escalation will be conducted in patients with advanced and/or metastatic solid tumors who are refractory to all standard of care therapies. Dose expansion will be conducted in two arms: Arm A will enroll patients with indications for which a checkpoint inhibitor (CPI) is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1 treatment regimen, and Arm B will enroll patients with tumor types for which CPI therapy is not indicated/approved.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with relapsed/refractory advanced or metastatic solid tumors
Drug: WTX-330
WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen
Drug: WTX-330
WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved
Drug: WTX-330
Investigation Product
Incidence of Dose Limiting Toxicities (DLTs)
A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol
Time frame: 4 weeks
Incidence of Treatment Emergent Adverse Events
AEs were graded and documented in accordance with NCI-CTCAE version 5.0
Time frame: 24 months
Incidence of Changes in Clinical Laboratory Abnormalities
Change from baseline is provided as baseline grade or "normal/low/high" and worst post-baseline grade.
Time frame: 24 months
Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)
RECIST = Response Evaluation Criteria in Solid Tumors
Time frame: 24 months
Plasma Concentrations of WTX-330 Cycle 1 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of WTX-330 Cycle 1 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of WTX-330 Cycle 1 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Plasma Concentrations of WTX-330 Cycle 2 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of WTX-330 Cycle 2 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of WTX-330 Cycle 2 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Plasma Concentrations of IL-12 Cycle 1 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of IL-12 Cycle 1 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Plasma Concentrations of IL-12 Cycle 1 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Plasma Concentrations of IL-12 Cycle 2 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of IL-12 Cycle 2 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Plasma Concentrations of IL-12 Cycle 2 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Antidrug Antibody (ADA) Occurrence
ADA were measured at Baseline and Post Baseline. "Positive" post baseline applies if at least one post-baseline value was positive.
Time frame: 24 months
Participants were recruited based on their oncological history at 9 clinical research sites in the United States.
| Milestone | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg |
|---|---|---|---|---|---|
| Started | 3 | 3 | 5 | 5 | 9 |
| Completed | 2 | 2 | 2 | 0 | 2 |
| Not completed | 1 | 1 | 3 | 5 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 | 3 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 3 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 2 | 1 |
A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol
| Participants | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Incidence of Dose Limiting Toxicities (DLTs) | 0 | 0 | 1 |
AEs were graded and documented in accordance with NCI-CTCAE version 5.0
| Participants | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) |
|---|---|---|---|---|---|
| TEAE | 3 | 3 | 5 | 5 | 9 |
| TEAEs Related to WTX-330 | 3 | 3 | 5 | 5 | 9 |
| Grade 3 or Higher TEAEs | 1 | 3 | 4 | 4 | 8 |
| Grade 3 or Higher TEAEs Related to WTX-330 | 1 | 2 | 4 | 3 | 5 |
| Serious TEAEs | 0 | 1 | 2 | 3 | 8 |
| Serious TEAEs Related to WTX-330 | 0 | 1 | 1 | 1 | 5 |
Change from baseline is provided as baseline grade or "normal/low/high" and worst post-baseline grade.
| Participants | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) |
|---|---|---|---|---|---|
| Anemia — Grade 0 - Grade 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia — Grade 0 - Grade 1 | 0 | 0 | 3 | 0 | 0 |
| Anemia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Anemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 1 - Grade 1 | 2 | 0 | 1 | 1 | 3 |
| Anemia — Grade 1 - Grade 2 | 1 | 2 | 0 | 0 | 4 |
| Anemia — Grade 1 - Grade 3 | 0 | 1 | 0 | 1 | 0 |
| Anemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 2 - Grade 2 | 0 | 0 | 1 | 1 | 1 |
| Anemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Anemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Anemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Anemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Anemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Anemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Anemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 - Grade 0 | 1 | 0 | 2 | 2 | 0 |
| Hypoalbuminemia — Grade 0 - Grade 1 | 2 | 2 | 2 | 0 | 6 |
| Hypoalbuminemia — Grade 0 - Grade 2 | 0 | 1 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 - Grade 2 | 0 | 0 | 1 | 1 | 3 |
| Hypoalbuminemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 - Grade 2 | 0 | 0 | 0 | 2 | 0 |
| Hypoalbuminemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 - Grade 0 | 3 | 2 | 5 | 5 | 8 |
| Hypoglycemia — Grade 0 - Grade 1 | 0 | 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 1 |
| Hypoglycemia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 - Grade 0 | 2 | 1 | 1 | 1 | 6 |
| Hypokalemia — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 - Grade 2 | 0 | 1 | 4 | 4 | 2 |
| Hypokalemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 - Grade 2 | 1 | 0 | 0 | 0 | 1 |
| Hypokalemia — Grade 2 - Grade 3 | 0 | 1 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 - Grade 0 | 1 | 2 | 3 | 4 | 7 |
| Hypomagnesemia — Grade 0 - Grade 1 | 1 | 0 | 1 | 0 | 2 |
| Hypomagnesemia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 - Grade 1 | 1 | 1 | 1 | 1 | 0 |
| Hypomagnesemia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 - Grade 0 | 2 | 0 | 1 | 1 | 2 |
| Hyponatremia — Grade 0 - Grade 1 | 0 | 2 | 3 | 1 | 1 |
| Hyponatremia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 - Grade 3 | 0 | 1 | 0 | 2 | 3 |
| Hyponatremia — Grade 1 - Grade 0 | 1 | 0 | 0 | 0 | 1 |
| Hyponatremia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Hyponatremia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 1 - Grade 3 | 0 | 0 | 1 | 0 | 1 |
| Hyponatremia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 - Grade 1 | 0 | 0 | 0 | 1 | 0 |
| Hyponatremia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 0 - Grade 0 | 0 | 1 | 1 | 3 | 1 |
| Lymphocyte count decreased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Lymphocyte count decreased — Grade 0 - Grade 2 | 0 | 0 | 1 | 1 | 0 |
| Lymphocyte count decreased — Grade 0 - Grade 3 | 2 | 1 | 3 | 0 | 1 |
| Lymphocyte count decreased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 - Grade 3 | 0 | 1 | 0 | 0 | 3 |
| Lymphocyte count decreased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 - Grade 3 | 1 | 0 | 0 | 1 | 1 |
| Lymphocyte count decreased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 2 |
| Lymphocyte count decreased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Missing | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 0 - Grade 0 | 1 | 1 | 2 | 2 | 4 |
| Platelet count decreased — Grade 0 - Grade 1 | 1 | 2 | 2 | 3 | 2 |
| Platelet count decreased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 2 |
| Platelet count decreased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 - Grade 2 | 1 | 0 | 1 | 0 | 1 |
| Platelet count decreased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Missing | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Platelet count decreased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 0 - Grade 0 | 0 | 1 | 1 | 3 | 3 |
| White blood cell decreased — Grade 0 - Grade 1 | 0 | 0 | 0 | 1 | 0 |
| White blood cell decreased — Grade 0 - Grade 2 | 2 | 1 | 2 | 0 | 3 |
| White blood cell decreased — Grade 0 - Grade 3 | 1 | 1 | 2 | 1 | 1 |
| White blood cell decreased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| White blood cell decreased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 1 |
| White blood cell decreased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Missing | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| White blood cell decreased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 0 - Grade 0 | 1 | 1 | 2 | 1 | 5 |
| Activated partial thromboplastin time prolonged — Grade 0 - Grade 1 | 1 | 1 | 1 | 2 | 0 |
| Activated partial thromboplastin time prolonged — Grade 0 - Grade 2 | 1 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 0 - Grade 3 | 0 | 0 | 1 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 1 - Grade 1 | 0 | 1 | 0 | 0 | 2 |
| Activated partial thromboplastin time prolonged — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Activated partial thromboplastin time prolonged — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 2 - Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Activated partial thromboplastin time prolonged — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Missing | 0 | 0 | 1 | 1 | 1 |
| Activated partial thromboplastin time prolonged — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 0 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Low - Grade 0 | 0 | 0 | 0 | 1 | 0 |
| Alanine aminotransferase increased — Normal - Grade 0 | 0 | 2 | 1 | 1 | 3 |
| Alanine aminotransferase increased — Normal - Grade 1 | 3 | 1 | 3 | 1 | 4 |
| Alanine aminotransferase increased — Normal - Grade 2 | 0 | 0 | 0 | 2 | 1 |
| Alanine aminotransferase increased — Normal - Grade 3 | 0 | 0 | 1 | 0 | 0 |
| Alanine aminotransferase increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — High - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Alanine aminotransferase increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Normal - Grade 0 | 0 | 2 | 0 | 1 | 2 |
| Alkaline phosphatase increased — Normal - Grade 1 | 0 | 0 | 3 | 0 | 1 |
| Alkaline phosphatase increased — Normal - Grade 2 | 0 | 0 | 1 | 1 | 0 |
| Alkaline phosphatase increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — High - Grade 0 | 3 | 0 | 1 | 2 | 4 |
| Alkaline phosphatase increased — High - Grade 1 | 0 | 0 | 0 | 0 | 2 |
| Alkaline phosphatase increased — High - Grade 2 | 0 | 1 | 0 | 1 | 0 |
| Alkaline phosphatase increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Low - Grade 0 | 0 | 0 | 1 | 0 | 0 |
| Aspartate aminotransferase increased — Normal - Grade 0 | 0 | 1 | 0 | 0 | 1 |
| Aspartate aminotransferase increased — Normal - Grade 1 | 1 | 2 | 3 | 2 | 4 |
| Aspartate aminotransferase increased — Normal - Grade 2 | 0 | 0 | 0 | 1 | 1 |
| Aspartate aminotransferase increased — Normal - Grade 3 | 0 | 0 | 1 | 1 | 0 |
| Aspartate aminotransferase increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — High - Grade 1 | 2 | 0 | 0 | 1 | 2 |
| Aspartate aminotransferase increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — High - Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Blood bilirubin increased — Grade 0 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Normal - Grade 0 | 1 | 1 | 2 | 2 | 5 |
| Blood bilirubin increased — Normal - Grade 1 | 2 | 1 | 2 | 3 | 1 |
| Blood bilirubin increased — Normal - Grade 2 | 0 | 1 | 1 | 0 | 1 |
| Blood bilirubin increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Blood bilirubin increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — High - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Blood bilirubin increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 0 - Grade 0 | 2 | 2 | 4 | 4 | 5 |
| Creatinine increased — Grade 0 - Grade 1 | 1 | 0 | 0 | 1 | 0 |
| Creatinine increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 2 |
| Creatinine increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 - Grade 1 | 0 | 1 | 1 | 0 | 1 |
| Creatinine increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 1 |
| Creatinine increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 0 - Grade 0 | 2 | 1 | 1 | 1 | 6 |
| GGT increased — Grade 0 - Grade 1 | 1 | 1 | 3 | 2 | 2 |
| GGT increased — Grade 0 - Grade 2 | 0 | 0 | 1 | 1 | 1 |
| GGT increased — Grade 0 - Grade 3 | 0 | 1 | 0 | 1 | 0 |
| GGT increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Missing | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| GGT increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 - Grade 0 | 3 | 3 | 5 | 5 | 9 |
| Hemoglobin increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 - Grade 0 | 3 | 3 | 5 | 5 | 8 |
| Hyperkalemia — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 1 |
| Hyperkalemia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 - Grade 0 | 3 | 3 | 4 | 5 | 9 |
| Hypermagnesemia — Grade 0 - Grade 1 | 0 | 0 | 1 | 0 | 0 |
| Hypermagnesemia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 - Grade 0 | 2 | 3 | 5 | 5 | 9 |
| Hypernatremia — Grade 0 - Grade 1 | 1 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Missing | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 0 - Grade 0 | 2 | 1 | 3 | 3 | 2 |
| INR increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 3 |
| INR increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 0 - Grade 3 | 0 | 1 | 0 | 0 | 0 |
| INR increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 2 | 1 |
| INR increased — Grade 1 - Grade 2 | 0 | 0 | 1 | 0 | 2 |
| INR increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 2 - Grade 2 | 1 | 1 | 1 | 0 | 1 |
| INR increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Missing | 0 | 0 | 0 | 0 | 0 |
| INR increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| INR increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| INR increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| INR increased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| INR increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| INR increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 - Grade 0 | 3 | 3 | 5 | 5 | 9 |
| Lymphocyte count increased — Grade 0 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 1 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 1 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 1 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 1 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 4 - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 4 - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 4 - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 4 - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 4 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 1 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 - Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Missing | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Low - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Normal - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Normal - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Normal - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Normal - Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — High - Grade 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — High - Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — High - Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — High - Grade 3 | 0 | 0 | 0 | 0 | 0 |
RECIST = Response Evaluation Criteria in Solid Tumors
| Percent of participants | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg |
|---|---|---|---|---|---|
| ORR by RECIST | 0 (0 to 70.8) | 33.3 (0.8 to 90.6) | 0 (0 to 70.8) | 0 (0 to 52.2) | 0 (0 to 41.0) |
| immune ORR by iRECIST | 0 (0 to 70.8) | 33.3 (0.8 to 90.6) | 0 (0 to 70.8) | 0 (0 to 52.2) | 0 (0 to 41.0) |
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| mcg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 1 - C Max | 0.2773 ± 0.11684 | 0.4290 ± 0.29465 | 0.8624 ± 0.17688 |
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| h | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation | 2.40 ± 3.637 | 2.93 ± 4.561 | 3.26 ± 1.668 |
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| day | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 1 - Half Life | 2.1886 ± 1.23394 | 2.7083 ± 1.00754 | 3.3463 ± 1.48342 |
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
| day*mcg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 1 - AUC | 0.7585 ± 0.50363 | 1.1952 ± 0.84243 | 1.7270 ± 0.75076 |
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| mcg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 2 - C Max | 0.3210 ± 0.04950 | 0.6272 ± 0.60613 | 1.0748 ± 0.70201 |
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| h | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation | 0.30 ± 0 | 1.40 ± 1.992 | 2.15 ± 2.136 |
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| day | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 2 - Half Life | 3.3296 ± 0.34454 | 2.8809 ± 1.73910 | 4.0216 ± 1.06686 |
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
| day*mcg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 2 - AUC | 1.0247 ± 0.14275 | 0.8744 ± 0.51499 | 1.8042 ± 0.80145 |
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| pg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 1 - C Max | 1434.7 ± 694.10 | 2298.0 ± 1434.71 | 3022.0 ± 787.48 |
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| h | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation | 4.90 ± 1.473 | 5.23 ± 2.065 | 6.48 ± 2.182 |
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
| day | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 1 - Half Life | 3.2138 ± 1.33405 | 3.2643 ± 1.26642 | 2.4809 ± 0.75436 |
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
| day*pg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 1 - AUC | 3221.5 ± 1879.29 | 5144.7 ± 3395.29 | 5986.4 ± 2336.59 |
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| pg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 2 - C Max | 1331.5 ± 26.16 | 2165.7 ± 1933.23 | 3292.8 ± 2236.70 |
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| h | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation | 13.80 ± 13.435 | 0.27 ± 0.058 | 2.95 ± 1.782 |
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
| day | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 2 - Half Life | 2.2540 ± 0.92905 | 3.8541 ± 0.92348 | 2.7120 ± 1.54085 |
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
| day*pg/ml | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg |
|---|---|---|---|
| Plasma Concentrations of IL-12 Cycle 2 - AUC | 3569.4 ± 636.45 | 1957.5 ± 635.67 | 4349.9 ± 1530.39 |
ADA were measured at Baseline and Post Baseline. "Positive" post baseline applies if at least one post-baseline value was positive.
| Participants | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg |
|---|---|---|---|---|---|
| ADA at Baseline — Negative | 2 | 3 | 4 | 5 | 8 |
| ADA at Baseline — Positive | 1 | 0 | 1 | 0 | 1 |
| ADA at Baseline — Unknown | 0 | 0 | 0 | 0 | 0 |
| ADA post Baseline — Negative | 2 | 2 | 2 | 3 | 5 |
| ADA post Baseline — Positive | 1 | 1 | 2 | 0 | 0 |
| ADA post Baseline — Unknown | 0 | 0 | 1 | 2 | 4 |
Collected over AEs were collected from the signing of the ICF for a median duration of 86 days (min 37, max 219). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| WTX-330 Dose Escalation - 0.024 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| WTX-330 Dose Escalation - 0.032 mg/kg | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | 3/5 (60%) | 3/5 (60%) | 5/5 (100%) |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | 5/9 (55.6%) | 8/9 (88.9%) | 9/9 (100%) |
| Event | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg |
|---|---|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 0/3 | 1/3 | 1/5 | 0/5 | 4/9 |
| FatigueGeneral disorders | 0/3 | 0/3 | 0/5 | 0/5 | 2/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/5 | 0/5 | 2/9 |
| Adrenocortical insufficiency acuteEndocrine disorders | 0/3 | 0/3 | 1/5 | 0/5 | 0/9 |
| GastritisGastrointestinal disorders | 0/3 | 0/3 | 0/5 | 1/5 | 0/9 |
| SepsisInfections and infestations | 0/3 | 0/3 | 0/5 | 1/5 | 1/9 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 0/5 | 1/5 | 0/9 |
| Malignant melanoma of sites other than skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/5 | 1/5 | 0/9 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/5 | 1/5 | 0/9 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 0/5 | 0/5 | 1/9 |
| Event | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 5/5 | 0/5 | 3/9 |
| ChillsGeneral disorders | 1/3 | 0/3 | 4/5 | 2/5 | 6/9 |
| Abdominal painGastrointestinal disorders | 1/3 | 2/3 | 0/5 | 0/5 | 0/9 |
| StomatitisGastrointestinal disorders | 0/3 | 2/3 | 0/5 | 2/5 | 1/9 |
| FatigueGeneral disorders | 2/3 | 2/3 | 3/5 | 1/5 | 3/9 |
| PyrexiaGeneral disorders | 2/3 | 1/3 | 3/5 | 3/5 | 4/9 |
| Cytokine release syndromeImmune system disorders | 1/3 | 2/3 | 2/5 | 3/5 | 2/9 |
| Alanine aminotransferase increasedInvestigations | 2/3 | 1/3 | 3/5 | 1/5 | 4/9 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 1/3 | 3/5 | 1/5 | 4/9 |
| DehydrationMetabolism and nutrition disorders | 2/3 | 0/3 | 0/5 | 1/5 | 0/9 |
| Age, Continuous(years) | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 63.3 ± 10.26 | 60.6 ± 11.55 | 68.2 ± 7.90 | 65.00 ± 11.00 | 61.8 ± 10.13 | 64.4 ± 9.44 |
| Sex: Female, Male(Participants) | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 2 | 5 | 2 | 1 | 12 |
| Male | 1 | 3 | 4 | 1 | 4 | 13 |
| Race (NIH/OMB)(Participants) | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 0 | 0 | 2 |
| White | 1 | 5 | 8 | 3 | 4 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | WTX-330 Dose Escalation - 0.016 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Escalation - 0.032 mg/kg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 1 | 0 | 3 |
| Not Hispanic or Latino | 1 | 5 | 9 | 2 | 5 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Dec 2024, 24 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 71. This study's 24 months is below that.
Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Werewolf Therapeutics, Inc.